Navigation Links
EntreMed Presents Initial Clinical Results for ENMD-2076
Date:2/9/2009

ined by reduction in tumor markers in ovarian and colorectal cancer patients. Dose escalation continues to determine the primary endpoints of the study, safety, pharmacokinetics and a Phase 2 dose.

During the symposium, EntreMed's Senior Director, Translational Research, William E. Fogler, Ph.D., presented results from a preclinical evaluation of ENMD-2076 in combination with cisplatin in a multi-drug resistant, triple-negative human breast carcinoma model. Triple-negative breast cancer is a specific subtype of breast cancer that does not express estrogen receptor, progesterone receptor, or Her2 genes. This subtype is more aggressive and less responsive to standard treatment and is also associated with poorer patient prognosis. Data show the combination is well tolerated when using a maximally tolerated dose of cisplatin and a range of ENMD-2076 doses. Studies demonstrate a substantial dose-dependent antitumor combination effect as assessed by tumor regression. The enhanced antitumor activity observed with the combination of ENMD-2076 and cisplatin, over either agent alone, is correlated to biomarkers of angiogenesis, proliferation and apoptosis. These results provide a rationale for the clinical evaluation of ENMD-2076 in tumors responsive to platinum compounds, and particularly in triple-negative breast disease refractory to standard of care agents.

To further expand the clinical development of ENMD-2076, EntreMed has received a No Objection Letter (NOL) from the Therapeutic Products Directorate of Health Canada on its Clinical Trial Application to conduct a clinical study in Canada for ENMD-2076 in patients with hematological malignancies. A Canadian Clinical Trial Application (CTA) is similar to a United States Investigational New Drug (IND) application. The Company plans to commence a Phase 1 study in patients with relapsed or refractory leukemias in Canada later this year.

In addition, the U.S. Food a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... HAYWARD, Calif. , July 6, 2015  Impax ... Larry Hsu , Ph.D. has resigned from the ... business activities. Dr. Hsu was a co-founder of Impax ... Chief Executive Officer from October 2006 until April 2014. ... Fred Wilkinson , Impax,s President and Chief Executive ...
(Date:7/6/2015)... , July 6, 2015 Akcea Therapeutics, ... ISIS ), announced today that the U.S. ... Designation to volanesorsen (ISIS-APOCIII Rx ) for the ... FCS is a rare genetic disease characterized by ... In a Phase 2 study published in the ...
(Date:7/6/2015)... , July 6, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore ... a leading retail drugstore chain in China ... stores, today announced that its board of directors has ... 2015, from Simin Zhang , chairman of the ... Drugstore Holding Ltd., an investment vehicle wholly owned by ...
Breaking Medicine Technology:Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6
... Scientific Pte. Ltd today announced that the National University ... in its groundbreaking study: Abdominal Wall Closure After ... of TIGR® Matrix (100% Resorbable) ... received DSRB approval on 9th September 2010. There are ...
... PennDOT and the Pennsylvania State Police are reminding motorists ... over-the-counter medication can be just as dangerous as driving ... PennDOT will work with state and municipal ... enforcement, with increased emphasis on driving under the influence ...
Cached Medicine Technology:National University Hospital Singapore Operates on Asia's 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Mesh 2National University Hospital Singapore Operates on Asia's 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Mesh 3PennDOT, State Police Caution Motorists About Dangers of Driving Under Influence of Legal Drugs 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... Medical Spa industries, announces the return of its complimentary educational webinar series ... aesthetic medical business leaders creates success for their clients through targeted marketing, sales, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ranks ... a particular demographic, however, fat reduction has become more than a way to ...
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... doTERRA, the ... to its executive management team. Most recently, Jowers held the position as Director of ... years. , After spending a decade building the institute, Jowers states that he was ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with the CHN ... same cancer. , “Receiving a cancer diagnosis is often the most traumatic experience ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... AGA Medical Corporation ("AGA,Medical") announced today that it ... and Welfare (MHLW) for its AMPLATZER(R) Duct Occluder ... used for the,non-surgical closure of patent ductus arteriosus ... occurs when a blood vessel known as the ...
... Medical Innovations, Inc. (NYSE: IMA ), a ... solutions, has introduced the pima(TM) analyzer, a ... The initial application of the instrument will be a ... instrument is one of several novel technologies under development ...
... national health care reform a top priority of the ... proposals swirling about Washington, D.C., and around the country, ... stepping up its efforts to identify and launch new ... care delivery systems.With health care reform a central feature ...
... awareness and knowledge of Daiichi Sankyo,s innovative treatmentsPARSIPPANY, N.J., ... it has established a subsidiary -- Daiichi Sankyo de ... Inc. is based in San Juan, and led by ... more than 20 years of experience in pharmaceutical sales ...
... FDA-approved once-daily amoxicillin will be promoted to health ... Pharmaceuticals, Inc. (Nasdaq: MBRK ), today ... extended-release) Tablets, 775mg, will begin on March 16, ... of its 270-person field force which will promote ...
... - Hard to Treat Diseases (HTDS) www.htdsmedical.com ... identified a cosmetics company as a potential merger candidate. ... is engaged in online sales of the "Melem" product. ... It has a wide variety of skin and lip ...
Cached Medicine News:Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 2Health News:AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder 3Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 2Health News:Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008 3Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 2Health News:Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery 3Health News:Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 2Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 3Health News:MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009 4Health News:Hard To Treat Diseases (HTDS) Set To Acquire Cosmetics Company 2
... determination of Ang II is ... the pharmacological effect and efficiency ... angiotensin converting enzyme inhibitors (ACE ... antagonists as well as for ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
... BD Directigen EZ RSV Test utilizes a new, ... one device for rapid RSV detection. The testing ... method whereby dried reagents have already been applied ... a two-step process, with clear-cut results shown by ...
Medicine Products: